<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-137150" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lipoprotein X-Induced Hyperlipidemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashorobi</surname>
            <given-names>Damilola</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Liao</surname>
            <given-names>Huijuan</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Damilola Ashorobi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Huijuan Liao declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-137150.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lipoprotein X (Lp-X)-induced hyperlipidemia is a rare condition primarily seen in liver dysfunction, notably in cholestasis-related conditions. This abnormal lipoprotein, Lp-X, lacks apolipoprotein B100 and contributes to severe elevations in cholesterol levels. While atherosclerosis is uncommon, Lp-X accumulation leads to skin xanthomas, thrombotic events, and hyperviscosity syndrome, potentially fatal complications. Diagnosis involves challenging laboratory interpretations due to interference with LDL calculations and apolipoprotein analyses. Management revolves around addressing the underlying liver dysfunction, considering therapies like ursodeoxycholic acid, obeticholic acid (for primary biliary cholangitis), and fibrate therapy in select cases. Plasmapheresis might be used for severe complications, but liver transplantation remains the definitive treatment for primary liver disease.</p>
        <p>This&#x000a0;activity discusses&#x000a0;the intricacies of hyperlipidemia associated with Lp-X accumulation, offering a comprehensive exploration of its unique etiology, clinical presentation, and management. While hyperlipidemia is a well-established risk factor for cardiovascular disease, LpX-induced hyperlipidemia presents a distinct clinical picture with no associated increase in cardiovascular risk. Instead, it is closely linked to cholestatic liver disorders, making its prognosis and management markedly different from conventional hyperlipidemia. Through course participation, participants will be equipped with the specialized knowledge needed to navigate the complexities of LpX-induced hyperlipidemia confidently.&#x000a0;An interprofessional team approach ensures a holistic and well-informed approach to managing&#x000a0;LpX-induced hyperlipidemia This collaborative effort not only enhances the competence of each team member but also optimizes patient care, leading to improved clinical outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the common causes of lipoprotein X-induced hyperlipidemia.</p></list-item><list-item><p>Assess the clinical features and distinctive lipid profile patterns associated with Lipoprotein X-induced hyperlipidemia to facilitate accurate and early diagnosis.</p></list-item><list-item><p>Implement the typical management and treatment considerations for patients with lipoprotein X-induced hyperlipidemia.</p></list-item><list-item><p>Explain the role of an interprofessional team in managing patients with lipoprotein X-induced hyperlipidemia to help improve clinical outcomes for these patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137150&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137150">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-137150.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperlipidemia is a well-established cause of cardiovascular disease and metabolic syndrome; however, there are many different types and causes of this condition. Common heritable causes of hyperlipidemia include familial combined hyperlipidemia of different phenotypes, familial defective apolipoprotein B, familial hypertriglyceridemia, and familial hypercholesterolemia. While most "typical" hyperlipidemias cause atherosclerosis and increase the risk of cardiovascular diseases, some hyperlipidemias may have little to no effect on atherogenesis. One such type of hyperlipidemia is lipoprotein X (Lp-X)-induced hyperlipidemia.</p>
        <p>Lp-X is an abnormal lipoprotein type most commonly seen in patients with liver dysfunction, specifically in those patients with intra- or extrahepatic cholestasis.<xref ref-type="bibr" rid="article-137150.r1">[1]</xref>&#x000a0;Lp-X has also been shown to accumulate in patients with primary biliary cirrhosis, obstructive liver disease, and lecithin&#x02013;cholesterol acyltransferase deficiency.<xref ref-type="bibr" rid="article-137150.r2">[2]</xref>&#x000a0;</p>
        <p>While cardiovascular events and atherogenesis are rare in this disease, Lp-X-induced hyperlipidemia has clinical manifestations and potentially fatal complications. Severe Lp-X accumulation in the serum can lead to generalized skin xanthomas, primarily consisting of foamy cells derived from lipid-laden macrophages,<xref ref-type="bibr" rid="article-137150.r2">[2]</xref>&#x000a0;and dramatic elevations in cholesterol levels occur. In severe cases, potentially fatal thrombotic events and hyperviscosity syndrome may occur.&#x000a0;</p>
        <p>Therefore, the prognosis and management of Lp-X-induced hyperlipidemia differ from true hyperlipidemia. Healthcare professionals must recognize Lp-X-induced hyperlipidemia when present and manage this condition accordingly to maximize clinical outcomes. This article will highlight the etiology, epidemiology, and management of patients with Lp-X-induced hyperlipidemia to help clinicians treat this condition appropriately and help enhance clinical outcomes for patients affected by this disease.&#x000a0;</p>
      </sec>
      <sec id="article-137150.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are 4 commonly reported etiologies of LpX-induced hyperlipidemia in the literature. They include cholestatic liver dysfunction, deficiency of the lecithin-cholesterol-acyl-transferase enzyme, graft vs host liver disease, and lipid infusion.<xref ref-type="bibr" rid="article-137150.r3">[3]</xref><xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0;</p>
        <p>Elevated levels of LpX typically occur in cases of liver dysfunction, irrespective of the underlying cause. Enzymes, notably the cholesterol 17 alpha-hydroxylase enzyme, typically facilitate the usual conversion of cholesterol into bile acids, attributing this phenomenon. Cholestasis prevents the normal formation of bile acids, leading to the formation of LpX.</p>
        <p>LpX is rich in phospholipid and unesterified cholesterol, with albumin as the primary protein component and apolipoprotein C (apo-C) on the surface.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0; The reticuloendothelial system and the kidneys clear LpX. Researchers historically linked Lpx with patients who had cholestatic diseases. LpX fails to exert feedback inhibition on cholesterol synthesis, which leads to hypercholesterolemia in obstructive jaundice.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0;Aside from primary biliary cholangitis, LpX elevation has also been seen in patients with cholestasis of pregnancy.</p>
        <p>This condition can also be present in patients with mutations in the enzyme that esterifies cholesterol (ie, lecithin&#x02013;cholesterol acyltransferase [LCAT]). Patients with LCAT deficiency will have a higher formation of LpX because of their inability to convert free cholesterol to cholesterol esters.<xref ref-type="bibr" rid="article-137150.r5">[5]</xref>&#x000a0;Total parenteral nutrition has been shown to cause an increase in the accumulation of unesterified cholesterol and phospholipids, which comprise&#x000a0;most of the structure of Lp-X.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref></p>
        <p>Of the identified causes, the most frequently noted cause of LpX-induced hyperlipidemia is cholestatic liver disease. Among the identified causes, cholestatic liver disease emerges as the most frequently noted cause of LpX-induced hyperlipidemia. More than 75% of patients diagnosed with primary biliary cholangitis exhibit hypercholesterolemia, characterized by elevated cholesterol levels.<xref ref-type="bibr" rid="article-137150.r6">[6]</xref>&#x000a0;Among the identified causes, cholestatic liver disease emerges as the most frequently noted cause of LpX-induced hyperlipidemia. More than 75% of patients diagnosed with primary biliary cholangitis exhibit hypercholesterolemia, characterized by elevated cholesterol levels.<xref ref-type="bibr" rid="article-137150.r7">[7]</xref>&#x000a0;Although patients with cholestatic disease exhibit marked derangements in serum lipids and a high frequency of dyslipidemias, the observed risk of cardiovascular events was noted to be similar to that in the general population.<xref ref-type="bibr" rid="article-137150.r8">[8]</xref></p>
      </sec>
      <sec id="article-137150.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hypercholesterolemia due to elevated lipoprotein X level is uncommon. Even among patients with difficult-to-treat hyperlipidemia and identifiable secondary causes, LpX-induced hyperlipidemia is not a common cause.<xref ref-type="bibr" rid="article-137150.r9">[9]</xref>&#x000a0;In contrast, dyslipidemia due to secondary causes is common but is usually secondary to excessive alcohol intake or uncontrolled diabetes mellitus.<xref ref-type="bibr" rid="article-137150.r9">[9]</xref>&#x000a0;</p>
        <p>Due to the rarity of this disease, epidemiologic data regarding its true incidence and prevalence is scarce. The majority of the data regarding this disorder consists of case reports of patients with severe cholestatic liver diseases. Among patients with liver disease, the prevalence of lipoprotein-X-induced hyperlipidemia is quite remarkable. According to one report, among 97 patients with liver disease, elevated lipoprotein X levels were found in 45% of patients with cholestatic features.<xref ref-type="bibr" rid="article-137150.r10">[10]</xref>&#x000a0;However, in patients with liver disease without cholestasis, LpX was not elevated. According to this study, the prevalence of lipoprotein X elevation varied in different cholestatic diseases, with extrahepatic obstruction of recent onset showing elevated lipoprotein X level in 75% of the cases.<xref ref-type="bibr" rid="article-137150.r10">[10]</xref></p>
      </sec>
      <sec id="article-137150.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Lipoprotein X is an abnormal lipoprotein that is rich in free cholesterol and phospholipids and is primarily in patients with cholestatic diseases.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0;Cholestatic diseases disrupt the conversion of cholesterol to bile acids, resulting in an accumulation of bile acids and cholesterol in plasma.<xref ref-type="bibr" rid="article-137150.r3">[3]</xref>&#x000a0;As described above, the hypercholesterolemia observed in cholestasis is due to the accumulation of the anomalous LpX.</p>
        <p>LpX is a low-density lipoprotein subfraction<xref ref-type="bibr" rid="article-137150.r11">[11]</xref>&#x000a0;that forms from a bile lipoprotein after acquiring small quantities of triglycerides, apo-C, and esterified cholesterol in the blood vessels.<xref ref-type="bibr" rid="article-137150.r3">[3]</xref>&#x000a0;&#x000a0;The reticuloendothelial system and the kidney mediate Lp-X catabolism, but the exact mechanisms of this process are poorly understood.<xref ref-type="bibr" rid="article-137150.r3">[3]</xref></p>
        <p>This accumulation of LpX leads to severe hypercholesterolemia. However, there is no evidence of increased cardiovascular events or risk with this disease.<xref ref-type="bibr" rid="article-137150.r7">[7]</xref><xref ref-type="bibr" rid="article-137150.r8">[8]</xref>&#x000a0;The mechanism behind this "protective" effect is not elucidated and remains under study. Studies suggest that LpX reduces low-density lipoprotein (LDL) atherogenicity by preventing LDL oxidation and provides "protection" for endothelial cells by preserving their integrity in hypercholesterolemia.<xref ref-type="bibr" rid="article-137150.r11">[11]</xref>&#x000a0;</p>
        <p>LpX resembles a "lamellar vesicle" with a diameter of 30 to 70 nm,<xref ref-type="bibr" rid="article-137150.r12">[12]</xref>&#x000a0;and has a density close to very low-density lipoprotein (VLDL) and LDL, which can alter the results of LDL calculations. Lp-X completely lacks apo-B in its structure.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref>&#x000a0;The lipid composition of LpX consists mainly of free cholesterol and phospholipids, with less than 5% comprising cholesterol esters and triglycerides. The surface of the albumin contains small apolipoproteins like apo-A1, apo-E, and apo-C, while its aqueous core dissolves these components.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref>&#x000a0;The lack of apo-B provides a long half-life in circulation.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref>&#x000a0;LpX is primarily removed from the plasma by the reticuloendothelial system (at the spleen).</p>
      </sec>
      <sec id="article-137150.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients typically come to attention when laboratory testing of serum lipids yields grossly abnormal results. Still, history and physical are some of the most important aspects of a patient's evaluation because they give clinicians a clue about the cause of the patient's presentation. Ask patients with hyperlipidemia asked about current medications, family history of severe hyperlipidemia, or premature cardiovascular disease. Familial hyperlipidemia should be a top differential if the patient has more than a single family member with severe hyperlipidemia or premature cardiovascular disease. If not, clinicians need to think about other reasons that could cause severe hyperlipidemia. Such reasons include liver disease, LCAT deficiency, and lipid infusion.</p>
        <p>Visual physical examination findings include the presence of jaundice, scleral icterus, right upper quadrant pain, or liver enlargement. Xanthomas could also be present in some of these patients. Xanthomas can be around the tendon, elbows, and palms. The cause of the xanthomas is a result of the formation of foam cells in macrophages of patients with severe hyperlipidemia.<xref ref-type="bibr" rid="article-137150.r13">[13]</xref></p>
        <p>In graft versus host disease, LpX-induced hypercholesterolemia presents with hypercholesterolemia on laboratory testing with xanthelasmas and cholesterolomas.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0;Patients with LCAT deficiency present with low concentrations of high-density lipoprotein (HDL), as well as anemia, corneal opacities, proteinuria, and chronic kidney disease.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0;</p>
        <p>Pseudohyponatremia is also a prominent feature of this disease. Consider the presence of LpX in all patients withj&#x000a0;pseudo-hyponatremia associated with cholestasis.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref></p>
        <p>LpX accumulation can also result in hyperviscosity syndrome. Patients may have rare presentations such as a central retinal vein thrombosis presenting with vision loss.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref></p>
      </sec>
      <sec id="article-137150.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>As stated above, most patients come to light when they have grossly abnormal lipid testing results with the presence of xanthomas. The serum cholesterol level usually exceeds 1000 mg/dL in patients with xanthomas.<xref ref-type="bibr" rid="article-137150.r15">[15]</xref></p>
        <p>Lipoprotein X (LPX) is a 30 to 70 nm lipid bilayer vesicle that encloses a&#x000a0;fluid compartment.<xref ref-type="bibr" rid="article-137150.r16">[16]</xref>&#x000a0;It has been reported to contain 66% phospholipids, 22% cholesterol esters, and 6% albumin.<xref ref-type="bibr" rid="article-137150.r17">[17]</xref>&#x000a0;It is frequently mistaken for LDL on routine lipid panel labs due to similar densities.<xref ref-type="bibr" rid="article-137150.r18">[18]</xref>&#x000a0;Lipoprotein-X differs distinctly from all other liver-derived atherogenic lipoproteins, including very large-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). This is because it does not have a micellar structure and does not contain apolipoprotein B100 (apo-B).&#x000a0;</p>
        <p>Patients suspected to have LpX-induced hyperlipidemia should have a serum metabolic panel, liver function testing, serum lipid measurement, and apo-B measured. However, care must be taken to account for the "errors" in measurement that can result from the presence of LpX.&#x000a0;The presence of LpX interferes not only with the LDL calculation from the Friedewald formula but also interferes with direct LDL assays.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;LpX can also interfere with the measurements of apolipoprotein E phenotype analysis, total protein, and serum electrolytes if indirect ion-selective electrodes are used.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;</p>
        <p>Direct measures of LpX are not widely available.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;Available methods for the detection of LpX include electrophoresis using agarose gel, ultracentrifugation, and magnetic spectroscopy.<xref ref-type="bibr" rid="article-137150.r4">[4]</xref>&#x000a0;The latter two are available only in specialized laboratories and are infrequently used in routine diagnosis. Agarose electrophoresis is more readily available but is not foolproof. One case report stated that a commercially available agarose electrophoresis set failed to clearly demonstrate the presence of LpX in their patient.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;Reviewing the results of other case reports, the authors concluded that&#x000a0;the presence of LpX manifests in different ways in electrophoresis and varies by patient, raising caution for the interpretation of agarose&#x000a0;electrophoresis.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;Detection of LpX using agarose gel electrophoresis utilizes the separation of lipoproteins according to their surface charge.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref>&#x000a0;After running the specimen on non-denaturing agarose gels, they are fixed with 55% ethanol and stained with a lipophilic dye (such as Sudan Black).<xref ref-type="bibr" rid="article-137150.r12">[12]</xref>&#x000a0;LPX, however, is difficult to detect using Sudan Black, which adheres to neutral lipids, because LPX particles are deficient in neutral lipids (such as cholesterol esters and triglycerides).<xref ref-type="bibr" rid="article-137150.r19">[19]</xref>&#x000a0;Filipin, a fluorescent polyene antibiotic, has been suggested as a novel alternative for the detection of LpX as it binds specifically to free cholesterol that is abundantly present in LpX.<xref ref-type="bibr" rid="article-137150.r19">[19]</xref></p>
        <p>Indirect measures of LpX utilize the absence of apo-B in this structure by measuring the total cholesterol to apo-B ratio or the discrepancy in calculated vs. measured LDL levels in a serum sample. The total cholesterol to apo-B ratio is usually significantly increased in patients with LpX-induced hypercholesterolemia.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;Some patients, however, may have only a slight increase in this ratio due to the co-existence of LpX elevation with LDL elevation. In these patients, the apo-B level is increased, lowering the total cholesterol to apo-B ratio.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref>&#x000a0;In such cases, a discrepancy of measured vs. calculated LDL may be used to demonstrate the presence of LpX. One case study reported total cholesterol of 982&#x02009;mg/dL, triglycerides of 115&#x02009;mg/dL, and HDL cholesterol of 32&#x02009;mg/dL, for a calculated LDL of 927&#x02009;mg/dL. In the same sample, the directly measured LDL cholesterol was 499&#x02009;mg/dL.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref> This difference can be used as an indirect measure of LpX as it is strongly suggestive of hypercholesterolemia secondary to LpX.&#x000a0;</p>
      </sec>
      <sec id="article-137150.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The definitive therapy for LpX-induced dyslipidemia is to treat the underlying cause. Statins are ineffective in lowering cholesterol in LpX-related hypercholesterolemia because LpX does not undergo LDL receptor-mediated hepatic clearance.<xref ref-type="bibr" rid="article-137150.r16">[16]</xref>&#x000a0;As bile excretion is affected, cholestasis also could lead to the accumulation of toxic levels of statins, most of which is&#x000a0;excreted in bile.<xref ref-type="bibr" rid="article-137150.r16">[16]</xref>&#x000a0;&#x000a0;Ezetimibe is also not effective because it works by helping to reduce intestinal cholesterol absorption. However, in cholestasis, there is poor micellar formation, leading to poor cholesterol absorption.<xref ref-type="bibr" rid="article-137150.r16">[16]</xref></p>
        <p>In patients with cholestatic diseases, ursodeoxycholic acid and obeticholic acid (OCA) can reduce lipid levels. Ursodeoxycholic acid can decrease total cholesterol and low-density lipoprotein (LDL) cholesterol in patients with primary biliary cholangitis (PBC).<xref ref-type="bibr" rid="article-137150.r20">[20]</xref>&#x000a0;Obeticholic acid can decrease total cholesterol and high-density lipoprotein (HDL) cholesterol in patients with PBC and respond poorly to ursodeoxycholic acid (UDCA).<xref ref-type="bibr" rid="article-137150.r21">[21]</xref>&#x000a0;</p>
        <p>It is important to note that OCA is contraindicated in patients with advanced cirrhosis.<xref ref-type="bibr" rid="article-137150.r22">[22]</xref>&#x000a0;The American Association for the Study of Liver Diseases defines advanced cirrhosis in this scenario as current or prior evidence of liver decompensation (eg, encephalopathy, coagulopathy) or portal hypertension (eg, ascites, gastroesophageal varices, or persistent thrombocytopenia).&#x000a0;</p>
        <p>Combining fibrate therapy with UDCA may be an option for patients who respond poorly to UDCA. Adding fenofibrate therapy to UDCA in patients with PBC who had an incomplete response to UDCA resulted in significant reductions in total cholesterol, triglycerides, and non-high-density lipoprotein cholesterol.<xref ref-type="bibr" rid="article-137150.r23">[23]</xref>&#x000a0;A 2018 study evaluated the effect of bezafibrate compared to placebo in patients with incomplete response to UDCA therapy. The study results reported that bezafibrate plus UDCA therapy resulted in a more significant reduction in total cholesterol level after 24 months compared with placebo plus UDCA.<xref ref-type="bibr" rid="article-137150.r24">[24]</xref>&#x000a0;According to the AASLP practice guidelines, fibrates can be considered an "off-label" treatment for patients who have PBC and inadequate response to ursodeoxycholic acid.<xref ref-type="bibr" rid="article-137150.r22">[22]</xref>&#x000a0;They advise caution and discourage the use of fibrates in patients with decompensated liver disease (Child Pugh-Turcotte B or C).<xref ref-type="bibr" rid="article-137150.r22">[22]</xref></p>
        <p>In patients with graft-vs-host disease (GVHD) of the liver causing LpX-induced hyperlipidemia, treatment of the underlying GVHD by adjustment of immunosuppression is the mainstay of therapy.<xref ref-type="bibr" rid="article-137150.r25">[25]</xref>&#x000a0;Adjustment of immunosuppression was shown to significantly improve or resolve hypercholesterolemia in 3 out of the 5 patients.<xref ref-type="bibr" rid="article-137150.r25">[25]</xref>&#x000a0;</p>
        <p>Initiate plasmapheresis in patients presenting with hyperviscosity syndrome, pulmonary embolism, or cholesteroloma of the lung.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref><xref ref-type="bibr" rid="article-137150.r25">[25]</xref>&#x000a0;Although the data regarding its efficacy is limited to case reports, most experts recommend plasmapheresis for the treatment of LpX-induced hypercholesterolemia that presents with hyperviscosity syndrome, thrombotic complications, graft-versus-host disease of the liver, and cholesteroloma of the lung.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref><xref ref-type="bibr" rid="article-137150.r25">[25]</xref>&#x000a0;Plasmapheresis, however, should be considered only as a temporary measure in most cases until a liver transplant, as this is the only definitive therapy for patients with primary liver disease.<xref ref-type="bibr" rid="article-137150.r12">[12]</xref></p>
      </sec>
      <sec id="article-137150.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis should include primary familial causes of severe hyperlipidemia and other common causes of secondary hyperlipidemia, including the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Familial hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Familial defective apo-B</p>
          </list-item>
          <list-item>
            <p>Familial combined hyperlipidemia</p>
          </list-item>
          <list-item>
            <p>Type III hypolipoproteinemia</p>
          </list-item>
          <list-item>
            <p>Excessive alcohol intake</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Uncontrolled diabetes mellitus</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-137150.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In most cases, hyperlipidemia resolves with adequate treatment of cholestatic disease. A case report by Patel AM et al (2016), discussed the normalization of lipid profiles in a patient with primary sclerosing cholangitis who developed hypercholesterolemia due to LpX after undergoing treatment with corticosteroids and azathioprine.<xref ref-type="bibr" rid="article-137150.r26">[26]</xref>&#x000a0;</p>
        <p>Cutaneous xanthomas associated with cholestasis typically regress within months.<xref ref-type="bibr" rid="article-137150.r18">[18]</xref>&#x000a0;Xanthomas are non-life threatening and asymptomatic. In most patients, they resolve with the treatment of underlying hyperlipidemia and cholestasis.&#x000a0;</p>
        <p>The risk of cardiovascular disease in patients with cholestatic diseases is generally not increased. Most studies evaluating this risk looked at patients with primary biliary cholangitis. Results from a 2008 study looking at 930 patients with primary biliary cholangitis concluded that there was no increased risk of myocardial infarction, stroke, or transient ischemic attack compared to age- and sex-matched controls.<xref ref-type="bibr" rid="article-137150.r7">[7]</xref></p>
      </sec>
      <sec id="article-137150.s11" sec-type="Complications">
        <title>Complications</title>
        <p>While LpX itself does not increase the risk of coronary artery disease, multiple case studies have linked it to hyperviscosity syndrome. Complications such as hyperviscosity syndrome and renal disease have been reported in patients with LCAT deficiency-associated hypercholesterolemia.<xref ref-type="bibr" rid="article-137150.r14">[14]</xref></p>
        <p>Cutaneous xanthomas are common in patients with this disease. One case report, however, noted the development of cutaneous xanthelasmas and diffuse gastric xanthomas secondary to lipoprotein X-induced hypercholesterolemia.<xref ref-type="bibr" rid="article-137150.r27">[27]</xref>&#x000a0;This patient had PBC-associated cirrhosis, and the gastric xanthomas resolved completely following liver transplantation.</p>
      </sec>
      <sec id="article-137150.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>There are no guidelines or specific recommendations in the current literature regarding screening for hyperlipidemia in patients at risk for lipoprotein X elevations. The screening guidelines for dyslipidemia in these patients should follow the universal dyslipidemia screening guidelines advised for the general population. According to the European Association for the Study of the Liver (EASL) practice guidelines, there is no substantial evidence to support increased cardiovascular risk in patients with hyperlipidemia associated with PBC.<xref ref-type="bibr" rid="article-137150.r28">[28]</xref>&#x000a0;They do not recommend any alternative screening schedule for these patients.&#x000a0;</p>
      </sec>
      <sec id="article-137150.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing LpX-induced hyperlipidemia requires collaboration and communication between clinicians who suspect the disease and laboratory personnel to effectively account for the discrepancies in laboratory measurement of serum lipids. The clinical nurses are also an essential part of the team as they help monitor patients for potential complications such as thrombotic events and can educate the patient regarding the clinical outcomes of this disease. Clinical pharmacists play a pivotal role in ensuring that the patient's medication list is reconciled to exclude any medications that may worsen their liver dysfunction or hyperlipidemia. A collaborative, well-integrated interprofessional team of clinicians, nurses, pharmacists, and laboratory personnel can significantly improve clinical outcomes for patients affected by this disease.</p>
      </sec>
      <sec id="article-137150.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137150&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137150">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/lipoprotein-x-induced-hyperlipidemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=137150">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/137150/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=137150">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-137150.s15">
        <title>References</title>
        <ref id="article-137150.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heimerl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boettcher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liebisch</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>1861</volume>
            <issue>8 Pt A</issue>
            <fpage>681</fpage>
            <page-range>681-7</page-range>
            <pub-id pub-id-type="pmid">27112638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lian</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Perrard</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Monocyte phenotyping and management of lipoprotein X syndrome.</article-title>
            <source>J Clin Lipidol</source>
            <year>2020</year>
            <season>Nov-Dec</season>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>850</fpage>
            <page-range>850-858</page-range>
            <pub-id pub-id-type="pmid">33011137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fellin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manzato</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein-X fifty years after its original discovery.</article-title>
            <source>Nutr Metab Cardiovasc Dis</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-8</page-range>
            <pub-id pub-id-type="pmid">30503707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crook</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein X: clinical implications.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>Pt 2</issue>
            <fpage>93</fpage>
            <page-range>93-4</page-range>
            <pub-id pub-id-type="pmid">23512171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norum</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Remaley</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Miettinen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Str&#x000f8;m</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Balbo</surname>
                <given-names>BEP</given-names>
              </name>
              <name>
                <surname>Sampaio</surname>
                <given-names>CATL</given-names>
              </name>
              <name>
                <surname>Wiig</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kuivenhoven</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tesmer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Skeie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karathanasis</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Manthei</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Retterst&#x000f8;l</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Lecithin:cholesterol acyltransferase: symposium on 50 years of biomedical research from its discovery to latest findings.</article-title>
            <source>J Lipid Res</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>1142</fpage>
            <page-range>1142-1149</page-range>
            <pub-id pub-id-type="pmid">32482717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crosignani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Battezzati</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Squarcia Giussani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zuin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Podda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.</article-title>
            <source>Gut</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-9</page-range>
            <pub-id pub-id-type="pmid">12117892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solaymani-Dodaran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aithal</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Card</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>2784</fpage>
            <page-range>2784-8</page-range>
            <pub-id pub-id-type="pmid">18759822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loaeza-Del Castillo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gayt&#x000e1;n-Santill&#x000e1;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Tello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merit</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Milke-Garc&#x000ed;a</surname>
                <given-names>MDP</given-names>
              </name>
              <name>
                <surname>Flores-Rodr&#x000ed;guez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alvirde-Garc&#x000ed;a</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis.</article-title>
            <source>Ann Hepatol</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>879</fpage>
            <page-range>879-882</page-range>
            <pub-id pub-id-type="pmid">31506216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vodnala</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rubenfire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Secondary causes of dyslipidemia.</article-title>
            <source>Am J Cardiol</source>
            <year>2012</year>
            <month>Sep</month>
            <day>15</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>823</fpage>
            <page-range>823-5</page-range>
            <pub-id pub-id-type="pmid">22658245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sherlock</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Occurrence of an abnormal lipoprotein in patients with liver disease.</article-title>
            <source>Gut</source>
            <year>1970</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1035</fpage>
            <page-range>1035-7</page-range>
            <pub-id pub-id-type="pmid">5511783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Morrisett</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Liau</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation.</article-title>
            <source>J Lipid Res</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>2116</fpage>
            <page-range>2116-22</page-range>
            <pub-id pub-id-type="pmid">15314101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kattah</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puerto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moreno-Pallares</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Jaramillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mendivil</surname>
                <given-names>CO</given-names>
              </name>
            </person-group>
            <article-title>Hypercholesterolemia Due to Lipoprotein X: Case Report and Thematic Review.</article-title>
            <source>Clin Med Insights Endocrinol Diabetes</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1179551419878687</fpage>
            <pub-id pub-id-type="pmid">31632171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiroi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ayaori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tozuka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miida</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages.</article-title>
            <source>J Clin Lipidol</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-118</page-range>
            <pub-id pub-id-type="pmid">28391876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00106;wikli&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mickiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kortas-Stempak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuchta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mucha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makowiecki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gliwi&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewandowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>P&#x00105;czek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fija&#x00142;kowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grucha&#x00142;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.</article-title>
            <source>J Med Biochem</source>
            <year>2020</year>
            <month>Sep</month>
            <day>02</day>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-289</page-range>
            <pub-id pub-id-type="pmid">33269016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorokin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.</article-title>
            <source>Atherosclerosis</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>194</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-9</page-range>
            <pub-id pub-id-type="pmid">17240380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>&#x000c5;berg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gylling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Isoniemi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.</article-title>
            <source>World J Hepatol</source>
            <year>2016</year>
            <month>Aug</month>
            <day>08</day>
            <volume>8</volume>
            <issue>22</issue>
            <fpage>924</fpage>
            <page-range>924-32</page-range>
            <pub-id pub-id-type="pmid">27574546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical laboratory characteristics of patients with obstructive jaundice accompanied by dyslipidemia.</article-title>
            <source>Clin Biochem</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>94</volume>
            <fpage>42</fpage>
            <page-range>42-47</page-range>
            <pub-id pub-id-type="pmid">33894198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Controversy over the atherogenicity of lipoprotein-X.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-123</page-range>
            <pub-id pub-id-type="pmid">30694826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Shamburek</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Neufeld</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karathanasis</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Remaley</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo.</article-title>
            <source>J Lipid Res</source>
            <year>2019</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1050</fpage>
            <page-range>1050-1057</page-range>
            <pub-id pub-id-type="pmid">30808683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poupon</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Ouguerram</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chr&#x000e9;tien</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Verneau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eschw&#x000e8;ge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Magot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poupon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.</article-title>
            <source>Hepatology</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-82</page-range>
            <pub-id pub-id-type="pmid">8477962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luketic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bodhenheimer</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Adorini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sciacca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beecher-Jones</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castelloe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.</article-title>
            <source>Gastroenterology</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>751</fpage>
            <page-range>751-61.e8</page-range>
            <pub-id pub-id-type="pmid">25500425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>1012</fpage>
            <page-range>1012-1013</page-range>
            <pub-id pub-id-type="pmid">34431119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liberopoulos</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Florentin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mikhailidis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Tsianos</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Fenofibrate in primary biliary cirrhosis: a pilot study.</article-title>
            <source>Open Cardiovasc Med J</source>
            <year>2010</year>
            <month>Apr</month>
            <day>28</day>
            <volume>4</volume>
            <fpage>120</fpage>
            <page-range>120-6</page-range>
            <pub-id pub-id-type="pmid">20556204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corpechot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chazouill&#x000e8;res</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Gruyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Habersetzer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mathurin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goria</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Potier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Minello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silvain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abergel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Debette-Gratien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Larrey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bronowicki</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Boursier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Ledinghen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Heurgue-Berlot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nguyen-Khac</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zoulim</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ollivier-Hourmand</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zarski</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Nkontchou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lemoinne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rainteau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lef&#x000e8;vre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Chaisemartin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chollet-Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaouar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Admane</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poupon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>07</day>
            <volume>378</volume>
            <issue>23</issue>
            <fpage>2171</fpage>
            <page-range>2171-2181</page-range>
            <pub-id pub-id-type="pmid">29874528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turchin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiebe</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Seely</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Soiffer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-9</page-range>
            <pub-id pub-id-type="pmid">15531904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Brautbar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Severe hypercholesterolemia and liver disease in a 3-year old.</article-title>
            <source>J Clin Lipidol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>650</fpage>
            <page-range>650-3</page-range>
            <pub-id pub-id-type="pmid">27206954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoppmann</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Al Diffalha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Gastric Xanthomatosis Secondary to Lipoprotein X in Primary Biliary Cholangitis.</article-title>
            <source>J Investig Med High Impact Case Rep</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>10</volume>
            <fpage>23247096221089488</fpage>
            <pub-id pub-id-type="pmid">35403472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137150.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <collab>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu</collab>
            <collab>European Association for the Study of the Liver</collab>
            <article-title>EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.</article-title>
            <source>J Hepatol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>145</fpage>
            <page-range>145-172</page-range>
            <pub-id pub-id-type="pmid">28427765</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
